Acquisitions (Tables)

6 Months Ended

Jun. 30, 2022

Business Combinations [Abstract]

Summary of Net Assets (Liabilities) Acquired

The net assets (liabilities) acquired were as follows (in thousands):

	Oppilan			Zomagen			Total
Cash and cash equivalents	$	1,748		$	151		$	1,899
Prepaid expenses and other assets		587			12			599
Property and equipment, net		10			6			16
Other long-term assets		—			7			7
Accounts payable		(453	)		(349	)		(802	)
Accrued expenses		(722	)		(854	)		(1,576	)
Net assets (liabilities) acquired	$	1,170		$	(1,027	)	$	143

Summary of Determination of Purchase Price and Related Charge to IPR&D

The determination of the purchase price and related charge to IPR&D as of December 31, 2021 is as follows (in thousands):

	Oppilan		Zomagen			Total
Net assets (liabilities) acquired	$	1,170	$	(1,027	)	$	143
Fair value of shares issued		13,498		7,534			21,032
Transaction fees		370		207			577
Fair value of vested common stock options exchanged		141		87			228
Purchase price		14,009		7,828			21,837
Acquired IPR&D	$	12,839	$	8,855		$	21,694